Novartis withdraws EU imatinib PAH filing
This article was originally published in Scrip
Novartis is withdrawing its centralized EU marketing application for approval of its targeted anticancer imatinib for the additional indication of pulmonary arterial hypertension (PAH).
You may also be interested in...
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.